cache/d441380020f0a7644e5142742319aa32853953191ea67633647dd266136e1ecc

COM:ALPHAMABONC

康宁杰瑞

  • Stock

HKD

Last Close

4.36

25/11 08:08

Market Cap

2.23B

Beta: -

Volume Today

2.94M

Avg: -

Company Overview

Metric
Company NameAlphamab OncologySierra Oncology
Symbol9.97K
MSH IDCOM:ALPHAMABONCCOM:SIERRAONCOLOGY
MarketSTOCKSPRIVATE
SectorHealthcareHealthcare & Health Services
IndustryBiotechnologyPharmaceuticals
CountryCNGB
Stage
Employee Count435
Websitealphamabonc.comsierraoncology.com
LinkedIn
Founders

Market Metrics

Metric
Market Cap286.50M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Financial Performance

Metric
Revenue30.09M
Revenue (LTM)
Revenue (NTM)
Gross Profit22.49M
EBITDA-38.90M
Operating Income-44.47M
Net Income-28.97M
EPS-0.03
Diluted EPS-0.03
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Growth Metrics

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Profitability Ratios

Metric
Gross Profit Margin0.79
Operating Profit Margin-1.11
EBITDA Margin-1.29
Net Profit Margin-0.84
Return on Equity-0.12
Return on Assets-0.09
Return on Capital Employed-0.16

Valuation Multiples

Metric
P/E Ratio-10.08
P/B Ratio2.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio21.63
EV Multiple-10.19

Operational Metrics

Metric
Days Sales Outstanding
Days Payables Outstanding62.85
Days Inventory Outstanding520.35
Operating Cycle532.25
Cash Conversion Cycle352.76
Asset Turnover0.12

Cash Flow Metrics

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt-0.29
Operating Cash Flow/Sales-0.34
Free Cash Flow Yield-0.13

Balance Sheet Metrics

Metric
Cash & Equivalents149.37M
Accounts Receivable
Inventory10.83M
Goodwill
Debt to Capitalization0.16
Debt to Assets0.16
Current Ratio3.88
Quick Ratio6.14

Efficiency Metrics

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue0.08
R&D to Revenue2.81
SG&A to Revenue0.52